Advancing syphilis diagnosis: multi-phase study evaluation of a TpN17-based double-antigen sandwich ELISA for detecting Treponema pallidum specific antibodies

TL;DR

This study evaluates a new ELISA test using the TpN17 protein to diagnose syphilis, showing high accuracy and agreement with existing tests.

Contribution

The study introduces and validates a TpN17-based double-antigen sandwich ELISA for syphilis with strong diagnostic metrics.

Findings

The TpN17-based ELISA showed an AUC of 98.7% and Cohen’s Kappa of 0.91 in phase I.

Phase II results included 100% specificity, 88.9% sensitivity, and a diagnostic odds ratio of 13,600.

Cross-reactivity was observed in 2.6–11.5% of samples for other diseases like Chagas and HCV.

Abstract

Syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum, has high incidence rates among adults, pregnant women, and newborns. Diagnostic procedures typically involve a treponemal test (such as ELISA, CMIA, and IFI), followed by a non-treponemal test (VDRL and RPR). This study aimed to assess the diagnostic performance of a double antigen sandwich ELISA (DAgS-ELISA) using the recombinant protein TpN17, analyzing serum samples from both infected and not infected with T. pallidum. A total of 712 samples were deemed eligible and recharacterized using VDRL, ELISA, and FTA-ABS, with 613 ultimately included in the evaluation: 180 T. pallidum-positive, 169 T. pallidum-negative, and 264 positive samples for other diseases. The assay was standardized using checkerboard titration and evaluated based on the area under the ROC curve (AUC), sensitivity, specificity, accuracy, likelihood values, diagnostic ratio, and Cohen’s Kappa index (κ). In phase I, positive and negative samples showed statistical differences (p < 0.0001) for the TpN17 protein. The ROC curve (AUC) was 98.7% and Cohen’s Kappa of 0.91, indicating almost perfect agreement with the reference tests. Phase II results demonstrated an AUC of 97.5%, specificity of 100%, sensitivity of 88.9%, accuracy of 94.3%, a positive likelihood ratio of 1.512, a negative likelihood ratio of 0.11, and a diagnostic odds ratio of 13,600, with a Cohen’s Kappa of 0.89. Cross-reactivity was observed in samples positive for Chagas disease (11.5%), HBV (2.6%), HCV (6.4%), and HTLV-1/2 (6.8%). Overall, TpN17 exhibited high diagnostic performance across all clinical stages of syphilis. Future research should expand the sample panel and explore new proteins to enhance DAgS-ELISA’s effectiveness and applicability for syphilis diagnosis across diverse clinical settings.

Figures